ABRA: The Potential Drug Target of Striated Muscle Activator of Rho-Dependent Signaling

Target Name: ABRA

NCBI ID: G137735

ABRA

ABRA: The Potential Drug Target of Striated Muscle Activator of Rho-Dependent Signaling

Introduction

Striated muscle activation of Rho-dependent signaling (SMAS) has been identified as a promising target for drug development due to its involvement in various physiological processes, including muscle growth, maintenance, and repair. The Rho family of small GTPases is a critical signaling pathway that regulates many cellular processes in eukaryotic cells, including cytoskeletal organization, cell adhesion, and signaling pathways. ABRA, or striated muscle activator of Rho-dependent signaling, is a protein that has been shown to promote muscle growth and maintenance, and it is considered as a potential drug target in the field of muscle physiology and neurodegenerative diseases.

ABRA: Structure and Function

The ABRA gene is located on chromosome X and encodes a protein that belongs to the Rho family of small GTPases. ABRA is a 21-kDa protein that consists of an N-terminal alpha-helix, a catalytic domain, and a C-terminal T -loop. The N-terminal region of ABRA contains a putative GTP-binding site, which is important for its signaling functions. The catalytic domain of ABRA contains a GAP- catalytic activity that allows it to activate GTPases. The C-terminal region of ABRA contains a regulatory domain that includes a GFP-like gene that encodes a protein that can interact with ABRA and modulate its activity.

ABRA has been shown to play a crucial role in several physiological processes, including muscle growth and maintenance. It has been shown that ABRA can promote muscle cell proliferation and survival, as well as increase the number of muscle fibers. Additionally, ABRA has been shown to regulate muscle protein synthesis and contribute to muscle mass development.

ABRA has also been shown to be involved in various signaling pathways, including the Rho-dependent signaling pathway. This pathway is involved in the regulation of cellular processes that are critical for cell survival and growth, including cell adhesion, cytoskeletal organization, and signaling pathways that regulate cell proliferation and differentiation. The Rho-dependent signaling pathway is activated by various factors, including ABRA, which can then regulate the activity of several downstream targets, including the RhoA GTPase, which is involved in the regulation of cellular processes that are critical for cell survival and growth.

Drug Targeting

ABRA is considered a potential drug target due to its involvement in various physiological processes and its role in the Rho-dependent signaling pathway. Several studies have shown that ABRA can be targeted by small molecules, including inhibitors of the RhoA GTPase. These inhibitors can inhibit the activity of ABRA and the RhoA GTPase, leading to the inhibition of the Rho-dependent signaling pathway.

One of the most promising strategies for targeting ABRA is the use of small molecules that can inhibit the activity of the RhoA GTPase. Several inhibitors have been shown to be effective in inhibiting the activity of the RhoA GTPase, including:

1. Compound 1 (C1): C1 is a small molecule that can inhibit the activity of the RhoA GTPase. C1 has been shown to be effective in inhibiting the activity of the RhoA GTPase in cell culture and in animal models of neurodegenerative diseases.
2. Compound 2 (C2): C2 is another small molecule that can inhibit the activity of the RhoA GTPase. C2 has been shown to be effective in inhibiting the activity of the RhoA GTPase in cell culture and in animal models of neurodegenerative diseases.
3. Compound 3 (C3): C3 is a small molecule that can inhibit the activity of the RhoA GTPase. C3 has been shown to be effective in inhibiting the activity of the RhoA GTPase in cell culture and in animal models of neurodegenerative diseases.

Conclusion

ABRA is a protein that has been shown to play a crucial role in various physiological processes, including muscle growth and maintenance. Its role in the Rho-dependent signaling pathway makes it a potential drug target in the field of muscle physiology and neurodegenerative diseases. The use of small molecules that can inhibit the activity of the RhoA GTPase, such as compound 1 (C1), compound 2 (C2), and compound 3 (C3), provides a promising strategy for targeting ABRA and its role in the development of new treatments for muscle physiology and neurodegenerative diseases. Further studies are needed to confirm the effectiveness of these small molecules as potential drug targets and to develop safe and effective treatments.

Protein Name: Actin Binding Rho Activating Protein

Functions: Acts as an activator of serum response factor (SRF)-dependent transcription possibly by inducing nuclear translocation of MKL1 or MKL2 and through a mechanism requiring Rho-actin signaling

The "ABRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets